1. Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
   Wiwit Nurhidayah et al, 2022, Molecules CrossRef
2. Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis
   Xiaojun Qi et al, 2015, La radiologia medica CrossRef
3. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation
   Yewei Liu et al, 2020, Diagnostics CrossRef
4. Combretastatin A4‐phosphate and its potential in veterinary oncology: a review
   E. Abma et al, 2017, Veterinary and Comparative Oncology CrossRef
5. Avenues to molecular imaging of dying cells: Focus on cancer
   Anna A. Rybczynska et al, 2018, Medicinal Research Reviews CrossRef
6. Evans Blue Dye: A Revisit of Its Applications in Biomedicine
   Linpeng Yao et al, 2018, Contrast Media & Molecular Imaging CrossRef
7. Mechanisms Regulating Muscle Regeneration: Insights into the Interrelated and Time-Dependent Phases of Tissue Healing
   Laura Forcina et al, 2020, Cells CrossRef
8. An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications
   Marlein Miranda Cona, 2013, World Journal of Methodology CrossRef
9. 131I-Evans blue: evaluation of necrosis targeting property and preliminary assessment of the mechanism in animal models
   Qiaomei Jin et al, 2018, Acta Pharmaceutica Sinica B CrossRef
10. Biodistribution and tolerance of intravenous iodine‐131‐labelled hypericin in healthy dogs
    E. Abma et al, 2018, Veterinary and Comparative Oncology CrossRef